Atmospheric Thermodynamic Profiling through the Use of a Micro-Pulse Raman Lidar System: Introducing the Compact Raman Lidar MARCO

It was for a long time believed that lidar systems based on the use of high-repetition micro-pulse lasers could be effectively used to only stimulate atmospheric elastic backscatter echoes, and thus were only exploited in elastic backscatter lidar systems. Their application to stimulate rotational and roto-vibrational Raman echoes, and consequently, their exploitation in atmospheric thermodynamic profiling, was considered not feasible based on the technical specifications possessed by these laser sources until a few years ago. However, recent technological advances in the design and development of micro-pulse lasers, presently achieving high UV average powers (1–5 W) and small divergences (0.3–0.5 mrad), in combination with the use of large aperture telescopes (0.3–0.4 m diameter primary mirrors), allow one to presently develop micro-pulse laser-based Raman lidars capable of measuring the vertical profiles of atmospheric thermodynamic parameters, namely water vapor and temperature, both in the daytime and night-time. This paper is aimed at demonstrating the feasibility of these measurements and at illustrating and discussing the high achievable performance level, with a specific focus on water vapor profile measurements. The technical solutions identified in the design of the lidar system and their technological implementation within the experimental setup of the lidar prototype are also carefully illustrated and discussed

In-water lidar simulations: the ALADIN ADM-Aeolus backscattered signal at 355 nm

The Lidar Ocean Color (LiOC) Monte Carlo code has been developed to simulate the in-water propagation of the lidar beam emitted by the ALADIN ADM-Aeolus instrument in the ultraviolet (UV) spectral region (∼ 355 nm). To this end, LiOC accounts for reflection/transmission processes at the sea surface, absorption and multiple scattering in the water volume, and reflection from the sea bottom. The water volume components included in the model are pure seawater, Chlorophyll-a concentration (Chl-a), Colored Dissolved Organic Matter (CDOM), and/or a generic absorbing species. By considering the transmission/reception measurement geometry of ALADIN ADM-Aeolus, the study documents the variability of the normalized backscattered signal in different bio-optical conditions. The potential for data product retrieval based on information at 355 nm is considered by developing a demonstrative lookup table to estimate the absorption budget exceeding that explained by Chl-a. Results acknowledge the interest of space programs in exploiting UV bands for ocean color remote sensing, as, for instance, addressed by the PACE mission of NASA

Exploring the potential of Aeolus lidar mission for ocean color applications

The Atmospheric Laser Doppler Instrument (ALADIN) onboard the Aeolus wind mission was the first High Spectral Resolution Lidar operating in the Ultra Violet (UV) region deployed in space. This study explores and documents the feasibility of deriving ocean optical properties using data from ALADIN. A three steps (i.e. data screening, analytical estimation of the total in-water signal contribution, Look Up Table-based estimation of the in-water attenuation) retrieval algorithm was developped combining data analysis and signal simulations from a radiative transfer model. The algorithm has been implemented using the signal acquired by the Mie channel, and tested for 1-year of Aeolus observations. This approach allowed estimating the first Aeolus derived Ocean Color (OC) products in terms of the total in-water signal contribution and the in-water attenuation term in a spectral region (355 nm) not covered, during Aeolous lifetime, by operational OC products. The validation process involved comparing these products with both Biogeochemical-Argo (BGC-Argo) field measurements and satellite OC dataset distributed by ESA Ocean Color Climate Change Initiative across a set of 7 selected oceanic regions representing diverse open-ocean scenarios. These validation exercises attested the general accordance between OC reference measurements and the proposed Aeolus OC parameters. Thus, this study was able to provide statistical evidence of the sensitivity of the retrieved Aeolus in-water lidar attenuation term to the CDOM variability on a temporal/seasonal and spatial/regional basis. A preliminary estimation of the uncertainty associated to the retrieved quality controlled Klid, was performed assuming the radiometric noise as unique source of uncertainty. As a result, a median/average value of absolute relative percent difference of about 50/80% was obtained. Limits of the developed technique, possible improvements, potential adaptation to planned/future space lidar missions are discussed

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

INTRODUCTION: Hereditary transthyretin (ATTRv; v for variant) amyloidosis, also known as hATTR amyloidosis, is a progressive and fatal disease associated with rapid deterioration of physical function and patients' quality of life (QOL). Vutrisiran, a subcutaneously administered RNA interference (RNAi) therapeutic that reduces hepatic production of transthyretin, was assessed in patients with ATTRv amyloidosis with polyneuropathy in the pivotal HELIOS-A study. METHODS: The phase 3 open-label HELIOS-A study investigated the efficacy and safety of vutrisiran in patients with ATTRv amyloidosis with polyneuropathy, compared with an external placebo group from the APOLLO study of the RNAi therapeutic patisiran. Measures of QOL and physical function were assessed. RESULTS: At month 18, vutrisiran improved Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score (least squares mean difference [LSMD] in change from baseline [CFB]: –21.0; p = 1.84 × 10–10) and Norfolk QOL-DN domain scores, compared with external placebo. This benefit relative to external placebo was evident across all baseline polyneuropathy disability (PND) scores and most pronounced in patients with baseline PND scores I–II. Compared with external placebo, vutrisiran also demonstrated benefit in EuroQoL-Visual Analog Scale (EQ-VAS) score (LSMD in CFB: 13.7; nominal p = 2.21 × 10–7), 10-m walk test (LSMD in CFB: 0.239 m/s; p = 1.21 × 10–7), Rasch-built Overall Disability Score (LSMD in CFB: 8.4; p = 3.54 × 10–15), and modified body mass index (mBMI) (LSMD in CFB: 140.7; p = 4.16 × 10–15) at month 18. Overall, Norfolk QOL-DN, EQ-VAS, and mBMI improved from pretreatment baseline with vutrisiran, whereas all measures worsened from baseline in the external placebo group. At month 18, Karnofsky Performance Status was stable/improved from baseline in 58.2/13.1% with vutrisiran versus 34.7/8.1% with external placebo. CONCLUSION: Vutrisiran treatment provided significant clinical benefits in multiple measures of QOL and physical function in patients with ATTRv amyloidosis with polyneuropathy. Benefits were most pronounced in patients with earlier-stage disease, highlighting the importance of early diagnosis and treatment

Micro-leakage at the implant-abutment interface with different tightening torques in vitro

OBJECTIVES: This study evaluated the microleakage at the implant/abutment interface of external hexagon (EH) implants and abutments with different amounts of bacteria and tightening torques. MATERIAL AND METHODS: A bacterial suspension was prepared to inoculate the implants. The first phase of this study used nine EH implants and abutments that were divided into three groups with different amounts of bacterial suspension (n=3): V0.5: 0.5 µL; V1.0: 1.0 µL e V1.5: 1.5 µL, and tightened to the manufacturer's recommended torque. The second phase of this experiment used 27 assemblies that were similar to those used in the first phase. These samples were inoculated with 0.5 µL of bacterial suspension and divided into three groups (n=9). T10: 10 Ncm; T20: 20 Ncm and T32: 32 Ncm. The samples were evaluated according to the turbidity of the broth every 24 hours for 14 days, and the bacteria viability was tested after that period. The statistical evaluation was conducted by Kruskal-Wallis testing (p<.05). RESULTS: During the first phase, groups V1.0 and V1.5 was presented with bacterial contamination in all samples after 24 h. During the second phase, two samples from group T10 and one from T20 presented positive results for bacterial contamination. Different amounts of bacterial solution led to overflow and contamination during the first 24 h of the experiment. The tightening torques did not statistically affect the microleakage in the assemblies. However, the group that was tightened to 32 Ncm torque did not show any bacterial contamination. CONCLUSION: After 14 days of experimentation, the bacteria were proven to remain viable inside the implant internal cavity

Mouthwashes for the control of supragingival biofilm and gingivitis in orthodontic patients: evidence-based recommendations for clinicians

Properly performed daily mechanical biofilm control is the most important prevention strategy for periodontal diseases. However, proper mechanical biofilm control is not performed effectively by the majority of the population, mainly due to lack of motivation and of manual dexterity. Local biofilm retention factors may aggravate home oral hygiene quality. For this reason, patients wearing fixed orthodontic appliances comprise a group that may benefit from the daily use of mouthwashes. The purpose of this review was to perform a systematic search in the literature on antiseptics used to control supragingival biofilm and gingivitis in orthodontic patients. Six studies investigating the effect of chlorhexidine and 5 studies evaluating the effect of the daily use of antiseptics were found. Chlorhexidine showed better results in reducing plaque and gingivitis. However, because of its adverse effects after continuous use, it should not be indicated for long-term periods. Among the agents considered for daily use, the fixed combination of essential oils was the only one evaluated in a clinical trial, in which a comparative group presented a statistically significant clinical impact. There is no direct evidence supporting the indication of antiseptic agents for orthodontic patients other than chlorhexidine and essential oils. It can be concluded that, for patients undergoing orthodontic treatment, chlorhexidine should be considered for treating acute gingival inflammation, whereas essential oils should be indicated for long-term daily use in controlling supragingival biofilm